Poster Station 1 (Rideau Canal Atrium) Moderator: Fraser Moore
P.101 - Miglustat: a first-in-class enzyme stabiliser for late-onset Pompe Disease P.102 - Clinical predictors of disease progression and survival in ALS: insights from the Canadian Neuromuscular Disease Registry P.103 - Effectiveness and safety of ravulizumab in generalized Myasthenia Gravis (gMG): Updated analysis from a global registry P.104 - A portrait of generalized Myasthenia Gravis in Canada: analysis of the Adelphi MG II disease specific programme P.105 - Therapeutic options for changing the course of disease in generalized myasthenia gravis (gMG) and fiscal consequences for Canadian governments P.106 - Investigating the bioequivalence, injection speed, and usability of subcutaneous efgartigimod PH20 administration using a prefilled syringe P.107 - Early and sustained response over time with zilucoplan in generalised Myasthenia Gravis: 120-week post hoc analysis of RAISE-XT P.109 - Pediatric quadriplegic CIDP: an update P.110 - A case of refractory NF155 paranodopathy with near complete sponteneous recovery
.png)
